The Potential of Serum Tenascin-C as a Biomarker of Severity and Progression in Coronary Artery Disease: a Narrative Review
DOI:
https://doi.org/10.15343/0104-7809.202650e18082025IKeywords:
Tenascin-C, Biomarker, Coronary Artery DiseaseAbstract
Tenascin-C (TNC) is an extracellular matrix glycoprotein whose expression in adults is associated with inflammatory and vascular remodeling processes, such as atherosclerosis. This exploratory narrative review resulted in the inclusion of studies that evaluated the association between serum TNC levels and the severity of Coronary Artery Disease (CAD). The findings indicate that TNC levels above 89.48 ng/mL exhibit a sensitivity of 86.4% and a specificity of 77.6% for identifying the presence of CAD, whereas values above 100.91 ng/mL are predictors of complex and severe coronary lesions (Gensini Score). It is concluded that serum TNC is a promising marker for risk stratification and monitoring of CAD progression, although its standardization in clinical practice requires validation in larger cohort studies.
Downloads
Download data is not yet available.
Translation
This article is a translation in English of the article:
O Potencial da Tenascina C Sérica como Biomarcador de Gravidade e Progressão na Doença Arterial Coronariana: uma Revisão Narrativa
References
Schaff M, Receveur N, Bourdon C, et al. Novel Function of Tenascin-C, a Matrix Protein Relevant to Atherosclerosis, in Platelet Recruitment and Activation Under Flow. Arterioscler Thromb Vasc Biol. 2011;31(1):117–24. doi: 10.1161/ATVBAHA.110.206375
Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-16823. doi: 10.1002/jcp.28350.
Shi X, Zhu S, Liu M, et al. Single-Cell RNA-Seq Reveals a Population of Smooth Muscle Cells Responsible for Atherogenesis. Aging Dis. 2022;13(6): 1939-1953. doi: 10.14336/AD.2022.0313.
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23(6):3346. doi: 10.3390/ ijms23063346.
Santos LCF, Paiva MAF de, Santana MVL, Mendes R, Tenório PP. Could we adopt serum Tenascin-C assays to determine prognosis in aortic aneurysms and dissections? J Vasc Bras. 2021;20:e20200165. doi: 10.1590/1677-5449.200165.
Imanaka-Yoshida K, Yoshida T, Miyagawa-Tomita S. Tenascin-C in Development and Disease of Blood Vessels. Anat Rec. 2014;297(9):1747–57. doi: 10.1002/ar.22985.
Giblin SP, Midwood KS. Tenascin-C: Form versus function. Cell Adhes Migr. 2015;9(1–2):48–82. doi: 10.4161/19336918.2014.987587.
Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 2016;jcs.190546. doi: 10.1242/jcs.190546.
Yuan W, Zhang W, Yang X, Zhou L, Hanghua Z, Xu K. Clinical significance and prognosis of serum tenascin-C in patients with sepsis. BMC Anesthesiol. 2018;18(1):170. doi: 10.1186/s12871-018-0634-1.
Mills JT, Schwenzer A, Marsh EK, et al. Airway Epithelial Cells Generate Pro-inflammatory Tenascin-C and Small Extracellular Vesicles in Response to TLR3 Stimuli and Rhinovirus Infection. Front Immunol. 2019;10:1987. doi: 10.3389/fimmu.2019.01987.
Silva AO da. A Tenascina-C e a sinalização celular na diferenciação tubulogênica endotelial. Rio de Janeiro. Dissertação [Mestrado em Biociências]. Universidade do Estado do Rio de Janeiro (UERJ); 2012.
Gao W, Li J, Ni H, et al. Tenascin C: A Potential Biomarker for Predicting the Severity of Coronary Atherosclerosis. J Atheroscler Thromb. 2019;26(1):31 38. doi: 10.5551/jat.42887.
Kentenich H, Müller D, Wein B, Stock S, Seleznova Y. Methods for assessing guideline adherence for invasive procedures in the care of chronic coronary artery disease: a scoping review. BMJ Open. 2023;13(3):e069832. doi: 10.1136/bmjopen-2022-069832.
Santos VP dos, Pozzan G, Castelli V, Caffaro RA. Arteriosclerose, aterosclerose, arteriolosclerose e esclerose calcificante da média de Monckeberg: qual a diferença? J Vasc Bras. 2021;20:e20200211. doi: 10.1590/1677-5449.200211.
Mehri H, Aslanabadi N, Nourazarian A, Shademan B, Khaki-Khatibi F. Evaluation of the serum levels of Mannose binding lectin-2, tenascin-C, and total antioxidant capacity in patients with coronary artery disease. J Clin Lab Anal. 2021;35(10):e23967. doi: 10.1002/jcla.23967. Epub 2021 Sep.
Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. Biomedicines. 2022;10(8):1938. doi: 10.3390/biomedicines10081938.
Mushenkova NV, Summerhill VI, Zhang D, Romanenko EB, Grechko AV, Orekhov AN. Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque. Int J Mol Sci. 2020;21(8):2992. doi: 10.3390/ijms21082992.
Ozmen Yildiz P, Yildiz I, Ozmen C, Karabacak M, Doven O. Relation between coronary artery calcium score and serum tenascin-C level in patients without known coronary artery disease. Acta Cardiol. 2015;70(6):633-639. doi: 10.2143/AC.70.6.3120174.
Yang JH, Ren F. Clinical implications of tenascin-C and OX40 ligand in patients with acute coronary syndrome. Biomed Rep. 2014 Jan;2(1):132-136.
Scheuner MT. Genetic evaluation for coronary artery disease. Genet Med. 2003;5(4):269–85. doi: 10.1097/01.GIM.0000079364.98247.26.
Jatene T, Mendonça JP, Vaz VD, Casas FRL, Casas RL de AL. Atherosclerotic Burden is the Highway to Cardiovascular Events.Arq. Bras. Cardiol., 2022 119(3)):400–1. doi: 10.36660/abc.20220554.
Carmo PB do, Magliano CAS, Rey HCV, Camargo GC, Trocado LFL, Gottlieb I. Cost-Effectiveness Analysis of CCTA in SUS, as Compared to Other Non-Invasive Imaging Modalities in Suspected Obstructive CAD. Arq Bras Cardiol. 2022; 118(3):578-585. doi: 10.36660/abc.20201050.
Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-16823. doi: 10.1002/jcp.28350.
Shi X, Zhu S, Liu M, et al. Single-Cell RNA-Seq Reveals a Population of Smooth Muscle Cells Responsible for Atherogenesis. Aging Dis. 2022;13(6): 1939-1953. doi: 10.14336/AD.2022.0313.
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23(6):3346. doi: 10.3390/ ijms23063346.
Santos LCF, Paiva MAF de, Santana MVL, Mendes R, Tenório PP. Could we adopt serum Tenascin-C assays to determine prognosis in aortic aneurysms and dissections? J Vasc Bras. 2021;20:e20200165. doi: 10.1590/1677-5449.200165.
Imanaka-Yoshida K, Yoshida T, Miyagawa-Tomita S. Tenascin-C in Development and Disease of Blood Vessels. Anat Rec. 2014;297(9):1747–57. doi: 10.1002/ar.22985.
Giblin SP, Midwood KS. Tenascin-C: Form versus function. Cell Adhes Migr. 2015;9(1–2):48–82. doi: 10.4161/19336918.2014.987587.
Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 2016;jcs.190546. doi: 10.1242/jcs.190546.
Yuan W, Zhang W, Yang X, Zhou L, Hanghua Z, Xu K. Clinical significance and prognosis of serum tenascin-C in patients with sepsis. BMC Anesthesiol. 2018;18(1):170. doi: 10.1186/s12871-018-0634-1.
Mills JT, Schwenzer A, Marsh EK, et al. Airway Epithelial Cells Generate Pro-inflammatory Tenascin-C and Small Extracellular Vesicles in Response to TLR3 Stimuli and Rhinovirus Infection. Front Immunol. 2019;10:1987. doi: 10.3389/fimmu.2019.01987.
Silva AO da. A Tenascina-C e a sinalização celular na diferenciação tubulogênica endotelial. Rio de Janeiro. Dissertação [Mestrado em Biociências]. Universidade do Estado do Rio de Janeiro (UERJ); 2012.
Gao W, Li J, Ni H, et al. Tenascin C: A Potential Biomarker for Predicting the Severity of Coronary Atherosclerosis. J Atheroscler Thromb. 2019;26(1):31 38. doi: 10.5551/jat.42887.
Kentenich H, Müller D, Wein B, Stock S, Seleznova Y. Methods for assessing guideline adherence for invasive procedures in the care of chronic coronary artery disease: a scoping review. BMJ Open. 2023;13(3):e069832. doi: 10.1136/bmjopen-2022-069832.
Santos VP dos, Pozzan G, Castelli V, Caffaro RA. Arteriosclerose, aterosclerose, arteriolosclerose e esclerose calcificante da média de Monckeberg: qual a diferença? J Vasc Bras. 2021;20:e20200211. doi: 10.1590/1677-5449.200211.
Mehri H, Aslanabadi N, Nourazarian A, Shademan B, Khaki-Khatibi F. Evaluation of the serum levels of Mannose binding lectin-2, tenascin-C, and total antioxidant capacity in patients with coronary artery disease. J Clin Lab Anal. 2021;35(10):e23967. doi: 10.1002/jcla.23967. Epub 2021 Sep.
Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. Biomedicines. 2022;10(8):1938. doi: 10.3390/biomedicines10081938.
Mushenkova NV, Summerhill VI, Zhang D, Romanenko EB, Grechko AV, Orekhov AN. Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque. Int J Mol Sci. 2020;21(8):2992. doi: 10.3390/ijms21082992.
Ozmen Yildiz P, Yildiz I, Ozmen C, Karabacak M, Doven O. Relation between coronary artery calcium score and serum tenascin-C level in patients without known coronary artery disease. Acta Cardiol. 2015;70(6):633-639. doi: 10.2143/AC.70.6.3120174.
Yang JH, Ren F. Clinical implications of tenascin-C and OX40 ligand in patients with acute coronary syndrome. Biomed Rep. 2014 Jan;2(1):132-136.
Scheuner MT. Genetic evaluation for coronary artery disease. Genet Med. 2003;5(4):269–85. doi: 10.1097/01.GIM.0000079364.98247.26.
Jatene T, Mendonça JP, Vaz VD, Casas FRL, Casas RL de AL. Atherosclerotic Burden is the Highway to Cardiovascular Events.Arq. Bras. Cardiol., 2022 119(3)):400–1. doi: 10.36660/abc.20220554.
Carmo PB do, Magliano CAS, Rey HCV, Camargo GC, Trocado LFL, Gottlieb I. Cost-Effectiveness Analysis of CCTA in SUS, as Compared to Other Non-Invasive Imaging Modalities in Suspected Obstructive CAD. Arq Bras Cardiol. 2022; 118(3):578-585. doi: 10.36660/abc.20201050.
Downloads
Published
2026-04-23
How to Cite
Carmo, V. E. S., Kamitani, H. Z., Carvalho, Ívine S., da Silva, W. M. M., Azevedo, J. P. L., Medrado, V. S. S., … Tenório, P. P. (2026). The Potential of Serum Tenascin-C as a Biomarker of Severity and Progression in Coronary Artery Disease: a Narrative Review. O Mundo Da Saúde, 50. https://doi.org/10.15343/0104-7809.202650e18082025I
Issue
Section
Articles
License
Copyright (c) 2026 O Mundo da Saúde
This work is licensed under a Creative Commons Attribution 4.0 International License.
